Intraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents

Cassese, Salvatore; Hoppmann, Petra; Kufner, Sebastian; Byrne, Robert A.; Wiebe, Jens; Colleran, Róisín; Giacoppo, Daniele; Harada, Yukinori; Laugwitz, Karl‐Ludwig; Schunkert, Heribert; Fusaro, Massimiliano; Kastrati, Adnan

doi:10.1161/circinterventions.116.003698

Cited by 3 publications

(5 citation statements)

References 28 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with previous data 10 , we found a lower minimum lumen diameter after PCI with Absorb as compared to EES, reflecting the intrinsic limitation of this technology. However, the treatment groups did not differ for this parameter at angiographic follow-up, suggesting a relatively stable mechanical behaviour of Absorb in STEMI patients, without instances of late recoil as previously observed 11 . Second, the risk for DOCE at 12 months was similar with Absorb and EES.…”

Section: Discussionsupporting

confidence: 71%

Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: a pooled analysis of individual patient data

Cassese¹,

Katagiri²,

Byrne³

et al. 2020

EuroIntervention

Self Cite

View full text Add to dashboard Cite

Aims: Bioresorbable scaffolds (BRS) were conceived to ensure transient coronary artery support during antiproliferative drug delivery. However, the Absorb everolimus-eluting bioresorbable scaffold was found to be inferior to everolimus-eluting metallic stents (EES) in moderately complex coronary anatomies. We sought to investigate whether the Absorb represents a valuable option for the percutaneous treatment of patients with ST-elevation myocardial infarction (STEMI). Methods and results:We pooled the individual patient data of two randomised trials specifically designed to investigate the performance of Absorb versus EES in patients with acute myocardial infarction (MI). The primary outcome was lesion (in-segment) diameter stenosis at angiographic follow-up. The main secondary outcome was the device-oriented composite endpoint (DOCE) of cardiac death, target vessel MI and target lesion revascularisation at one year. A total of 388 patients with STEMI were allocated to Absorb (n=227) or EES (n=161). Angiographic follow-up at one year was available for 332 (85.6%) patients. Lesion diameter stenosis was comparable between Absorb and EES (22.8±9.8% versus 23.6±11.2%; mean difference -0.8%, 95% confidence interval [CI]: -3.18-1.48, p=0.47). DOCE occurred in 21 patients at one year, with similar distribution between the Absorb and EES groups (5.3% versus 5.6%; hazard ratio 0.95, 95% CI: 0.40-2.26, p=0.91). Conclusions:This pooled analysis provides evidence for a comparable angiographic performance and suggests similar clinical performance of Absorb and EES in STEMI patients undergoing percutaneous revascularisation. The long-term durability of Absorb and the extent to which newer BRS platforms might have a potential role in STEMI deserve further investigation. Both trials were registered at www.clinicaltrials.gov (NCT01942070 and NCT01986803).

show abstract

Section: Discussionsupporting

confidence: 71%

Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: a pooled analysis of individual patient data

Cassese¹,

Katagiri²,

Byrne³

et al. 2020

EuroIntervention

Self Cite

View full text Add to dashboard Cite

show abstract

“…CAD is the leading cause of mortality and morbidity in the developed world ( 13 ). Numerous improvements have been made in coronary angioplasty, including balloon angioplasty, stenting and CABG, although a metallic scaffold device, alone or in combination with drug eluting stents (DESs) is considered to be the most effective method of treating CAD ( 14 ). However, studies have suggested that DESs delay re-endothelialization, which is important for the prevention of restenosis and stent thrombosis.…”

Section: Discussionmentioning

confidence: 99%

The effect of anagliptin on intimal hyperplasia of rat carotid artery after balloon injury

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

The present study evaluated the effect of anagliptin on intimal hyperplasia following carotid artery injury in Sprague-Dawley rats. Sprague-Dawley rats weighing 280–300 g were injured using a 2F Fogarty balloon embolectomy catheter. The rats were divided into injury-(saline) and anagliptin-(10 mg/kg/day) treated groups. vascular injuries were induced in the left carotid artery, followed by evaluation of neointima formation at 28 days. The right and left carotid arteries were harvested and evaluated with histological evaluation, and the plasma activity of glucagon-like peptide 1 receptor (GLP-1), stromal cell-derived factor (SDF)-1α, interleukin (IL)-6, IL-1β and tumor necrosis factor (TNF)-α were detected by ELISA analysis. Treatment with anagliptin decreased balloon injury-induced neointima formation, compared with the injury group (P<0.01). Body weight and food consumption did not alter following treatment with anagliptin. Anagliptin caused an increase in the serum active GLP-1 concentration, compared with the injury group. In addition, serum SDF-1α was significantly decreased by treatment with anagliptin (P<0.001). Anagliptin altered the serum activity of IL-6, IL-1β and TNF-α (P<0.01). The results of the present study demonstrated that anagliptin appeared to attenuate neointimal formation by inhibiting inflammatory cytokines and chemokines following balloon injury, and that treatment with a dipeptidyl peptidase 4 inhibitor may be useful for future preclinical studies and potentially for the inhibition of thrombosis formation following percutaneous coronary intervention.

show abstract

“…In this issue of Circulation: Cardiovascular Interventions, Cassese et al 5 report an intraindividual comparison of the performance of everolimus-eluting bioresorbable vascular scaffolds (BVS) versus durable metallic everolimus-eluting stents (DES) in the same individual but in different arteries. The 90 patients undergoing percutaneous coronary intervention to 239 lesions were assigned, at operator discretion, to receive a BVS (n=112) or DES (n=127).…”

Section: See Article By Cassese Et Almentioning

confidence: 99%

“…However, after adjustment for baseline angiographic differences, device type no longer significantly influenced late lumen loss. 5 This is not a randomized trial. Although the contribution of patient-related factors that may influence outcome between groups was controlled for in the study design, there were important baseline lesion-related differences.…”

Section: See Article By Cassese Et Almentioning

confidence: 99%

See 1 more Smart Citation

Of Stents and Scaffolds

Ormiston

Webster

2016

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

show abstract

Intraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents

Cited by 3 publications

References 28 publications

Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: a pooled analysis of individual patient data

Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: a pooled analysis of individual patient data

The effect of anagliptin on intimal hyperplasia of rat carotid artery after balloon injury

Of Stents and Scaffolds

Contact Info

Product

Resources

About